Breast Cancer Index^SM

Novel mechanism of action provides a new way to see breast cancer risk

bioTheranostics Breast Cancer Index^SM (BCI) is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients diagnosed with estrogen receptor-positive, lymph node-negative breast cancer. In development and validation studies, BCI stratified ~50% of tamoxifen treated ER+, node-negative breast cancer patients into a low risk group for 10-year distant recurrence.^6,7 BCI is a molecular assay developed from the combination of two indices:

HOXB13:IL17BR

• A two gene expression ratio biomarker linked to estrogen signaling in breast cancer.^1,2,3
• High HOXB13:IL17BR has been correlated with a poor prognosis in ER+/LN- breast cancer.

MGI⁵

• Five cell cycle-associate gene index that assesses tumor grade.*
• Advantages over histological tumor grade:
  • Stratifies patients with Grade 2 tumors into low and high risk of recurrence
  • Provides objective and quantitative assessment

These indices independently evaluate the status of endocrine signaling and mitogenic pathways. Each is individually predictive of clinical outcome in ER+, node-negative patients receiving adjuvant tamoxifen therapy. Combined, their use provides a more accurate prognosis for risk of recurrence at the patient level.⁵

*MGI measures BUB1B, CENPA, NEK2, RACGAP1, RRM2

BCI provides individual results as a continuous score ⁶

BCIs prognostic information is presented as a risk of recurrence score ranging from 0 to 10 and is categorized into three levels of risk:

Low < 5
Intermediate > 5 to < 6.4
High > 6.4

View the test report

The Breast Cancer Index test offers results that are objective, standardized, quantifiable and clinically insightful. Specimens are analyzed through bioTheranostics CLIA-certified, CAP accredited diagnostic service laboratory, which reports breast cancer recurrence risk in ER+, lymph node-negative patients in an easy-to-read format.

References